1-20 of 28
Mark G. Frattini, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

Stephane De Botton, Joseph M Brandwein, MD, Eytan M. Stein, MD, Andrew H. Wei, Daniela Weber, Arnaud Pigneux, Nicolas Boissel, MD PhD, Peter Paschka, MD, Konstanze Döhner, Salem Abi Nehme, Mark G. Frattini, MD, Roland Marion-Gallois, Jixian (Jason) Wang, Chris Cameron, Muhaimen Siddiqui, Rana A. Qadeer, Hartmut Döhner
Journal: Blood
Blood (2019) 134 (Supplement_1): 3893.
https://doi.org/10.1182/blood-2019-122700
Published: 2019
Journal Articles

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Kara Cicero, MD MPH, Mark L Heaney, Todd L. Rosenblat, MD MS, Nicole Lamanna, MD, Joseph G. Jurcic, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3899.
https://doi.org/10.1182/blood-2019-130203
Published: 2019
Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 643.
https://doi.org/10.1182/blood-2019-130362
Published: 2019
Journal Articles

Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy

Emily F Mason, MD PhD, Olga Pozdnyakova, MD PhD, Mikhail Roshal, MD PhD, Amir T. Fathi, MD, Eytan M. Stein, MD, Aaron C. Shaver, MD PhD, Mark G. Frattini, MD, Hongfang Wang, PhD, Lei Hua, PhD, Jimmy Mu, Caroline Almon, MS, Michael Cooper, MD, Richard M. Stone, MD, Robert P. Hasserjian, MD, Michael R. Savona, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1442.
https://doi.org/10.1182/blood-2019-123845
Published: 2019
Journal Articles

Comprehensive Genomic Analysis of IDH Inhibitor-Treated AML Samples Delineates Molecular Mechanisms of Differentiation and Heterogeneous Patterns of Acquired Resistance

Feng Wang, PhD, Kiyomi Morita, MD, Courtney D. DiNardo, MDMSc, Keyur Patel, MD PhD, Kyle MacBeth, PhD, Alessandra Tosolini, BS, Mark G. Frattini, MD, Jairo Matthews, BA, Latasha Little, Curtis Gumbs, Samantha Tippen, Xingzhi Song, PhD, Jianhua Zhang, PhD, Erika Thompson, MS, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Farhad Ravandi, MD, Marina Y. Konopleva, MD PhD, Hagop M. Kantarjian, MD, Andrew Futreal, PhD, Koichi Takahashi, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 441.
https://doi.org/10.1182/blood-2018-99-116383
Published: 2018
Journal Articles

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Michael Byrne, MD, Mark G. Frattini, MD PhD, Oliver G. Ottmann, MD, Ioannis Mantzaris, MD MS, Martin Wermke, MD, Daniel J. Lee, MD, Daniel Morillo, MD, Arne Scholz, PhD, Stuart Ince, PhD, Ray Valencia, MD, Fabricio Souza, MD, Raul Cordoba, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4055.
https://doi.org/10.1182/blood-2018-99-117257
Published: 2018
Journal Articles

Direct Comparison of in-Vitro Growth of Primary Human Acute Myeloid Leukemia (AML) Cells in Stromal and Stromal-Free Conditions

Jing Chen, MD, Glorymar Ibanez-Sanchez, Paul Calder, Mark G. Frattini, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5096.
https://doi.org/10.1182/blood-2018-99-116978
Published: 2018
Journal Articles

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Tara L Lin, MD, Carlos E Vigil, MD, Andrew Dalovisio, MD, Eunice S. Wang, MD, Moshe Yair Levy, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD, Pau Montesinos, MD PhD, Juan Miguel Miguel Bergua Burgues, Jeffrey R. Schriber, MD, Stephen Anthony, DO, David J. Bearss, PhD, B. Douglas Smith, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 30.
https://doi.org/10.1182/blood-2018-99-115018
Published: 2018
Journal Articles

Immunological Correlates of Treatment with the CTLA-4 Inhibitor Ipilimumab in Patients with Refractory Myelodysplastic Syndromes (MDS)

Tara M. Robinson, MD PhD, Hanna Knaus, MD, B Douglas Smith, MD, Andrea M.H. Towlerton, BS, Edus H. Warren, III, MDPhD, Joshua F Zeidner, MD, Amanda Blackford, Amy S. Duffield, MD PhD, David Rizzieri, MD, Mark G. Frattini, MD PhD, Moshe Levy, MD, Mark A. Schroeder, MD, Anna Ferguson, BSN, RN, Katherine Sheldon, Amy E. DeZern, MD, Ivana Gojo, MD, Steven D. Gore, MD, Howard Streicher, MD, Leo Luznik, MD, Amer M. Zeidan, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1699.
https://doi.org/10.1182/blood.V130.Suppl_1.1699.1699
Published: 2017
Journal Articles

Stroma-Based Versus Stroma-Free Long-Term Survival and Proliferation of Primary Acute Myeloid Leukemia (AML) Cells

Jing Chen, MD, Glorymar Ibanez-Sanchez, Paul Calder, Mark G. Frattini, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5569.
https://doi.org/10.1182/blood.V130.Suppl_1.5569.5569
Published: 2017
Journal Articles

Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies

Daniel J. Lee, MD, Todd L. Rosenblat, MD MS, Mark Lawrence Heaney, MD PhD, Joseph G. Jurcic, MD, Azra Raza, MD, Kristina Gazivoda, Katherine Harwood, Ryan Shelton, Hakim Djaballah, PhD, Joseph M. Scandura, MD PhD, Anthony Letai, MD PhD, Mark G. Frattini, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2816.
https://doi.org/10.1182/blood.V128.22.2816.2816
Published: 2016
Journal Articles

Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression

Jeffrey R Gardner, BS, MBA, Michelle Nahas, PhD, Jie He, PhD, Shlomzion Aumann, Mithat Gonen, Minal Patel, Kristina M. Knapp, BS, Maria Lia Palomba, MD, Roman Yelensky, PhD, Amy L Donahue, MS, Geoff Otto, PhD, Maria Arcila, MD, Nicole Lamanna, Mark G. Frattini, MD PhD, Ahmet Dogan, MD PhD, Jae H Park, MD, Doron Lipson, PhD, Martin S. Tallman, MD, Ross L. Levine, MD, Philip J. Stephens, PhD, Marcel R. M. van den Brink, MD PhD, Mark L Heaney, MD PhD, Vincent A. Miller, MD, Andrew D. Zelenetz, MD PhD, Omar Abdel-Wahab, MD
Journal: Blood
Blood (2014) 124 (21): 1954.
https://doi.org/10.1182/blood.V124.21.1954.1954
Published: 2014
Journal Articles

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

Todd Rosenblat, MD, Mark L. Heaney, MD PhD, Joseph G Jurcic, MD, Azra Raza, MD, John G. Mears, MD, Ruth Santos, BS, Diana Carrillo, BS, David Shum, MS, Jacquelyn Gonzales, BSN, RN, Kevin Zikaras, BS, Martin Santos, BS, Rong Zhang, MS, Glorymar Ibanezs, MS, Leah Hogdal, BA, Jennifer Crombie, MD, Hakim Djaballah, PhD, Joseph M. Scandura, MD PhD, Anthony G. Letai, MD PhD, Mark G. Frattini, MD PhD
Journal: Blood
Blood (2014) 124 (21): 974.
https://doi.org/10.1182/blood.V124.21.974.974
Published: 2014
Journal Articles

Micafungin Versus Posaconazole Anti-Fungal Prophylaxis in Adult Patients with Acute Leukemia Undergoing Induction Chemotherapy

Elizabeth Halton, RN, MS, ANP, Dick Chung, BS, Kun Xiao, MS, MPH, Hilda Quintanilla, RN, MS, ANP, Christina Baldwin, RN, MS, ANP, Pamela Baird, RN, MS, ANP, Ellin Berman, MD, Renier J Brentjens, MD, PhD, Mark Heaney, MD, PhD, Joseph G. Jurcic, MD, Nicole Lamanna, MD, Todd L. Rosenblat, MD, Rana Kaplan, MD, Genovefa Papanicolaou, MD, Mark G. Frattini, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 3556.
https://doi.org/10.1182/blood.V120.21.3556.3556
Published: 2012
Journal Articles

Molecular Remission and B Cell Aplasia Induced in a First Cohort of Adults with Relapsed B-ALL Treated with 19–28z CAR-Targeted T Cells

Marco L Davila, MD, PhD, Isabelle Riviere, PhD, Xiuyan Wang, PhD, Jae H. Park, MD, Jolanta Stefanski, Clare Taylor, MSc, Qing He, Malgorzata Olszewska, Teresa Wasielewska, Oriana Borquez-Ojeda, Jinrong Qu, Shirley Bartido, PhD, Joseph G. Jurcic, MD, Dan Douer, MD, Mark G. Frattini, MD, PhD, Michel Sadelain, MD, PhD, Renier J Brentjens, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 3566.
https://doi.org/10.1182/blood.V120.21.3566.3566
Published: 2012
Journal Articles

Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR)

Todd L. Rosenblat, MD, Mark G. Frattini, MD, PhD, Suzanne M. Chanel, RN, Tao Dao, MD, PhD, Yvette Bernal, Joseph G. Jurcic, MD, Rhong Zhang, Pamela Simancek, Martin S Tallman, MD, David A. Scheinberg, MD, PhD, Peter G. Maslak, M.D.
Journal: Blood
Blood (2012) 120 (21): 3624.
https://doi.org/10.1182/blood.V120.21.3624.3624
Published: 2012
Journal Articles

High Dose Cytarabine and Mitoxantrone in Combination with Dasatinib As Active Induction Therapy in Adult Patients with Philadelphia Chromosome Positive (ph+) Acute Lymphoblastic Leukemia (ALL)

Nicole Lamanna, MD, Mark Weiss, MD, Ellin Berman, MD, Mark G. Frattini, MD, PhD, Mark Heaney, MD, PhD, Joseph G. Jurcic, MD, Todd L. Rosenblat, MD, Heather Landau, MD, Hanna Weissbrot, BA, Peter G. Maslak, M.D.
Journal: Blood
Blood (2012) 120 (21): 4293.
https://doi.org/10.1182/blood.V120.21.4293.4293
Published: 2012
Journal Articles

Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.

Jeffrey R Gardner, MBA, Sean Devlin, PhD, Kristina Knapp, Francesco Bauli, MS, Nicole Lamanna, MD, Mark G. Frattini, MD, PhD, Renier J Brentjens, MD, PhD, Peter G. Maslak, M.D., Joseph G. Jurcic, MD, Mark Weiss, MD, David A. Scheinberg, MD, PhD, Mark Heaney, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2482.
https://doi.org/10.1182/blood.V120.21.2482.2482
Published: 2012
Journal Articles

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne M. Chanel, RN, Kevin Zikaras, BS, Mark G. Frattini, MD, PhD, Peter G. Maslak, M.D., Dragan Cicic, MD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 768.
https://doi.org/10.1182/blood.V118.21.768.768
Published: 2011
Journal Articles

Measuring Mitochondrial Apoptotic Priming by BH3 Profiling Predicts Induction Outcome for Acute Myeloid Leukemia Patients

Thanh-Trang T Vo, MD, Richard Stone, MD, Daniel J DeAngelo, MD, PhD, Mark G. Frattini, MD, PhD, Anthony G. Letai, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 239.
https://doi.org/10.1182/blood.V118.21.239.239
Published: 2011